Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy Life Science Investing
FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat Pharmaceutical Investing
Clearside Biomedical Submits New Drug Application for XIPERE for the Treatment of Macular Edema Associated with Uveitis Pharmaceutical Investing
G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib Pharmaceutical Investing
Cardiol Therapeutics Completes Initial Public Offering and the Company’s Common Shares and Warrants Commence Trading on the Toronto Stock Exchange Under the Symbols “CRDL” and “CRDL.WT” Cannabis Investing News
Hemispherx Biopharma Announces First Large Ampligen Shipment to a Clinical Site Pharmaceutical Investing
Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million Pharmaceutical Investing
Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial Life Science Investing
